PDE4A and idiopathic pulmonary fibrosis: In summary, BI 1015550 is an oral preferential inhibitor of PDE4B with suggested improved tolerability in humans compared with the selective oral PDE4 inhibitors on the market; the preclinical profile suggests that this compound is a promising oral clinical drug candidate for the treatment of IPF and other ILDs.